Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction with bortezomib, lenalidomide and dexamethasone (VRd) to treat ...
The outcomes from the Phase III IMROZ study support the decision. Sanofi Oncology global head Olivier Nataf stated: “In recent years, new multiple myeloma cases have increased steadily in Japan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback